-transparent.png){kind=logo}
The antidepressant efficacy and safety of milnacipran, a dual action antidepressant drug which inhibits the reuptake of serotonin and noradrenaline, was compared with that of the tricyclic antidepressant, imipramine, in a multi-centre, double-blind, randomised, parallel group, comparative trial in 5 hospital centres in Spain. One hundred patients hospitalised with a diagnosis of major depressive disorder according to the Diagnostic and Statistical Manual of the American Psychiatry Association (third revision), with a minimum score of 25 on the Montgomery and Asberg Depression Rating Scale were treated for 6 weeks with milnacipran (100 mg/day) or imipramine (150 mg/day). Both treatments showed similar efficacy in reducing depressive symptoms. The frequency of most adverse events in the milnacipran-treated patients was lower than that observed in the imipramine group, particularly those related to anticholinergic symptoms. Dysuria and shivering, however, were more common with milnacipran. The results of this study support others which have demonstrated that milnacipran has equivalent efficacy but superior tolerability to a tricyclic antidepressant such as imipramine.
J J Lopez-Ibor, and
A Conesa, and
September 1997,
International clinical psychopharmacology,
J J Lopez-Ibor, and
A Conesa, and
July 1989,
Pharmacopsychiatry,
J J Lopez-Ibor, and
A Conesa, and
August 2004,
Human psychopharmacology,
J J Lopez-Ibor, and
A Conesa, and
January 1987,
Drugs under experimental and clinical research,
J J Lopez-Ibor, and
A Conesa, and
January 1986,
Psychopharmacology,
J J Lopez-Ibor, and
A Conesa, and
June 2003,
The Journal of clinical psychiatry,
J J Lopez-Ibor, and
A Conesa, and
October 2014,
The Chinese journal of physiology,
J J Lopez-Ibor, and
A Conesa, and
January 2011,
Clinical neuropharmacology,
J J Lopez-Ibor, and
A Conesa, and
January 1994,
International clinical psychopharmacology,
J J Lopez-Ibor, and
A Conesa, and
July 1991,
Pharmacopsychiatry,
